Full access

LETTER

Published Online: 1 July 2007

A Novel View on the Pharmacodynamics of Rosiglitazone and Introducing Some Potential Drugs in Ameliorating Alzheimer’s Disease

Shahriar Gharibzadeh, M.D., Ph.D. and Sayed Shahabuddin Hoseini, M.D.Authors Info & Affiliations

Publication: The Journal of Neuropsychiatry and Clinical Neurosciences

https://doi.org/10.1176/jnp.2007.19.3.349

SIR: Alzheimer’s disease is a progressive and fatal neurodegenerative disorder manifested by cognitive and memory deterioration, progressive impairment of daily living activities, and a variety of neuropsychiatric symptoms and behavioral disturbances.

Increasing evidence shows that neurotoxicity is mediated by CNS inflammatory processes, which involve activation of the microglia by the amyloid-beta, leading to the release of proinflammatory cytokines, including interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha). Neurotoxic processes mediated by these cytokines may include direct neuronal death by enhancement of apoptosis, decreased synaptic function, and inhibition of hippocampal neurogenesis. 1

Rosiglitazone is used in some studies for improving the symptoms of Alzheimer’s disease but there is controversy about its mechanism of action. 2

There is evidence that shows the effect of rosiglitazone in reducing IL-6. 3 Although a study has shown that rosiglitazone cannot reduce IL-6, 4 it seems that this study was not maintained long enough to determine this effect.

In addition, a study showed that poor sleep is associated with higher interleukin-6 in older caregivers of people with Alzheimer’s disease. 5

According to aforementioned studies, we hypothesize that one of the mechanisms of action of rosiglitazone in ameliorating Alzheimer’s disease is reducing IL-6. Moreover, it seems that this drug can improve the sleep of people with Alzheimer’s disease.

Prescribing other IL-6 reducers as clenbuterol may be a good treatment for Alzheimer’s disease. On the other hand, TNF-alpha antagonists, like thalidomide, infliximab, etanercept, and adalimumab, may be effective in Alzheimer’s disease.

Surely, clinical trials are needed to validate our hypothesis.

References

Rosenberg PB: Clinical aspects of inflammation in Alzheimer’s disease. Int Rev Psychiatry 2005; 17:503–514

Google Scholar

Watson GS, Cholerton BA, Reger MA, et al: Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry 2005; 13:950–958

Google Scholar

Esposito K, Ciotola M, Carleo D, et al: Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome. Diabetes Care 2006; 29:1071–106

Google Scholar

Hetzel J, Balletshofer B, Rittig K, et al: Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers. Arterioscler Thromb Vasc Biol 2005; 25:1804–1809

Google Scholar

von Kanel R, Dimsdale JE, Ancoli-Israel S, et al: Poor sleep is associated with higher plasma proinflammatory cytokine interleukin-6 and procoagulant marker fibrin D-dimer in older caregivers of people with Alzheimer’s disease. J Am Geriatr Soc 2006; 54:431–437

Google Scholar

Information & Authors

Information

Published In

The Journal of Neuropsychiatry and Clinical Neurosciences

Volume 19 • Number 3 • Summer, 2007

Pages: 349

PubMed: 17827434

History

Published online: 1 July 2007

Published in print: Summer, 2007

Authors

Affiliations

Shahriar Gharibzadeh, M.D., Ph.D.

View all articles by this author

Sayed Shahabuddin Hoseini, M.D.

Neuromuscular Systems Laboratory, Department of Biomedical Engineering, Amirkabir University of Technology, Tehran, Iran

View all articles by this author

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format	RIS (ProCite, Reference Manager) EndNote BibTex Medlars RefWorks
Direct importt
Citation style
Style

Copy to clipboard
Tips for downloading citations

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login

Purchase Options

Purchase this article to access the full text.

PPV Articles - Journal of Neuropsychiatry and Clinical Neurosciences

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR^® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

A Novel View on the Pharmacodynamics of Rosiglitazone and Introducing Some Potential Drugs in Ameliorating Alzheimer’s Disease

References